|
The 1.8 A crystal structure of a proteinase K-like enzyme from a psychrotroph Serratia species
|
journal
|
January 2006 |
|
Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists
|
journal
|
August 2017 |
|
Annexin A2 Is a C-terminal PCSK9-binding Protein That Regulates Endogenous Low Density Lipoprotein Receptor Levels
|
journal
|
November 2008 |
|
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia
|
journal
|
April 2007 |
|
Bioactive Cyclization Optimizes the Affinity of a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Peptide Inhibitor
|
journal
|
December 2020 |
|
Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents
|
journal
|
January 2018 |
|
Data processing and analysis with the autoPROC toolbox
|
journal
|
March 2011 |
|
Flexizymes for genetic code reprogramming
|
journal
|
May 2011 |
|
Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design
|
journal
|
November 2020 |
|
Design of Organo-Peptides As Bipartite PCSK9 Antagonists
|
journal
|
January 2020 |
|
Annexin A2 Reduces PCSK9 Protein Levels via a Translational Mechanism and Interacts with the M1 and M2 Domains of PCSK9
|
journal
|
June 2014 |
|
Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation
|
journal
|
April 2007 |
|
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
|
journal
|
April 2020 |
|
Small Molecule Inhibitors of the PCSK9·LDLR Interaction
|
journal
|
January 2018 |
|
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|
journal
|
May 2017 |
|
A receptor-mediated pathway for cholesterol homeostasis
|
journal
|
April 1986 |
|
From Screening to Targeted Degradation: Strategies for the Discovery and Optimization of Small Molecule Ligands for PCSK9
|
journal
|
January 2020 |
|
Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix
|
journal
|
October 2019 |
|
Time-Averaged Distributions of Solute and Solvent Motions: Exploring Proton Wires of GFP and PfM2DH
|
journal
|
November 2014 |
|
A Small-Molecule Anti-secretagogue of PCSK9 Targets the 80S Ribosome to Inhibit PCSK9 Protein Translation
|
journal
|
November 2016 |
|
Design and Synthesis of Truncated EGF-A Peptides that Restore LDL-R Recycling in the Presence of PCSK9 In Vitro
|
journal
|
February 2014 |
|
Fragment-based design of small molecule PCSK9 inhibitors using simulated annealing of chemical potential simulations
|
journal
|
December 2019 |
|
Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation
|
journal
|
July 2012 |
|
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
|
journal
|
May 2003 |
|
Molecular basis for LDL receptor recognition by PCSK9
|
journal
|
February 2008 |
|
PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide
|
journal
|
October 2008 |
|
Engineered EGF-A Peptides with Improved Affinity for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
|
journal
|
January 2021 |
|
Coot model-building tools for molecular graphics
|
journal
|
November 2004 |
|
LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153–421): Design, synthesis and biochemical evaluation
|
journal
|
March 2015 |
|
XDS
|
journal
|
January 2010 |
|
Design of Thioether Cyclic Peptide Scaffolds with Passive Permeability and Oral Exposure
|
journal
|
February 2021 |
|
Pharmacologic Profile of the Adnectin BMS-962476, a Small Protein Biologic Alternative to PCSK9 Antibodies for Low-Density Lipoprotein Lowering
|
journal
|
June 2014 |
|
The Crystal Structure of PCSK9: A Regulator of Plasma LDL-Cholesterol
|
journal
|
May 2007 |
|
Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH
|
journal
|
November 2011 |
|
How proteins bind macrocycles
|
journal
|
July 2014 |
|
Liver-Targeted Small-Molecule Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9 Synthesis
|
journal
|
November 2017 |
|
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation
|
journal
|
August 2016 |
|
A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove
|
journal
|
March 2020 |
|
Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor
|
journal
|
November 2013 |
|
The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain
|
journal
|
September 2007 |
|
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|
journal
|
November 2018 |
|
Disrupting the PCSK9/LDLR protein–protein interaction by an imidazole-based minimalist peptidomimetic
|
journal
|
January 2016 |
|
TRAP Display: A High-Speed Selection Method for the Generation of Functional Polypeptides
|
journal
|
March 2013 |
|
Calcium-Independent Inhibition of PCSK9 by Affinity-Improved Variants of the LDL Receptor EGF(A) Domain
|
journal
|
October 2012 |